Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open Label, Controlled Study of Lopinavir/Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.

NCT01237444 is registered in ClinicalTrials.gov with Pedro Cahn as lead sponsor.

NCT NCT01237444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01237444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open Label, Controlled Study of Lopinavir/Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
Lead sponsor
Pedro Cahn
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
May 31, 2012
Enrollment
417 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection